New combo therapy for head and neck cancer shows promise but study halted early
Disease control
Terminated
This study tested whether adding danvatirsen to the standard immunotherapy pembrolizumab could help people with advanced head and neck cancer that has come back or spread. About 69 adults with incurable disease were planned to join, with two-thirds getting the combination and one…
Phase: PHASE2 • Sponsor: Flamingo Therapeutics NV • Aim: Disease control
Last updated May 26, 2026 11:28 UTC